GlassScriptPhysician profile
Michelle A Bock
NPI 1124423165
$3,513.46
in general payments reported to CMS, 2019-2025
48 companies · $936 in 2025
The $936 reported for 2025 was more than what 84% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $433 · 2023: $1,097 · 2024: $1,047 · 2025: $936.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,981 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,981.42 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $446.38 | 2022-2025 | Tecvayli, Darzalex, Erleada |
| Novartis Pharmaceuticals Corporation | $349.51 | 2022-2025 | |
| Abbvie INC. | $204.93 | 2023-2025 | |
| Eisai INC. | $156.66 | 2023-2025 | |
| Seagen INC. | $154.33 | 2022-2023 | Tukysa |
| Genzyme Corporation | $152.42 | 2022-2023 | |
| Aveo Pharmaceuticals, INC. | $150.19 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $128.03 | 2023-2025 | Keytruda, Lynparza, Welireg |
| Daiichi Sankyo INC. | $124.00 | 2023-2025 | Enhertu, Datroway, Injectafer |
| Regeneron Healthcare Solutions, INC. | $118.88 | 2023-2025 | Libtayo |
| Astrazeneca Pharmaceuticals LP | $109.21 | 2022-2024 | Enhertu, Calquence |
| Boehringer Ingelheim Pharmaceuticals, INC. | $79.74 | 2023-2025 | Gilotrif |
| E.R. Squibb & Sons, L.L.C. | $79.71 | 2024-2025 | Opdivo |
| Adc Therapeutics America, INC. | $73.67 | 2023-2025 | |
| Adaptive Biotechnologies Corporation | $72.54 | 2023-2025 | Clonoseq |
Show all 48 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tersera Therapeutics LLC | $69.34 | 2022-2023 | Zoladex |
| Pfizer INC. | $60.02 | 2022-2024 | |
| Novocure INC. | $59.87 | 2023-2024 | Optune Lua (Novottf-200t), Optune |
| Alexion Pharmaceuticals, INC. | $59.60 | 2023-2024 | Ultomiris |
| Karyopharm Therapeutics INC. | $58.17 | 2022-2023 | Xpovio |
| Genentech USA, INC. | $54.85 | 2023-2025 | Alecensa, Tecentriq, Rozlytrek |
| Takeda Pharmaceuticals U.S.A., INC. | $54.02 | 2023-2024 | Fruzaqla |
| Exelixis INC. | $47.81 | 2024-2025 | Cabometyx |
| Emd Serono, INC. | $47.14 | 2024-2025 | |
| G1 Therapeutics, INC. | $40.30 | 2023 | Cosela |
| Beigene USA, INC. | $40.27 | 2023-2024 | Brukinsa |
| Astellas Pharma US INC | $39.55 | 2024-2025 | Padcev, Xospata |
| Rigel Pharmaceuticals, INC. | $38.76 | 2022-2023 | Tavalisse, Rezlidhia |
| Beone Medicines USA, INC. | $38.31 | 2025 | Brukinsa |
| Progenics Pharmaceuticals, INC. | $37.74 | 2025 | |
| Sobi, INC | $35.05 | 2022-2024 | |
| Geron Corporation | $31.28 | 2025 | Rytelo |
| Morphosys, US INC. | $28.19 | 2023 | Monjuvi |
| Pharming Healthcare, INC. | $25.85 | 2023 | Ruconest |
| Immunogen, INC. | $23.40 | 2023 | Elahere |
| Genmab U.S., INC. | $22.44 | 2023 | Tivdak |
| Alnylam Pharmaceuticals INC. | $22.16 | 2023 | Onpattro |
| Acrotech Biopharma INC. | $19.26 | 2023 | Beleodaq |
| Deciphera Pharmaceuticals INC. | $18.18 | 2025 | Qinlock |
| Teleflex LLC | $17.72 | 2025 | Arrow |
| Jazz Pharmaceuticals INC. | $17.38 | 2025 | |
| Collegium Pharmaceutical, INC. | $16.57 | 2024 | Belbuca |
| Bayer Healthcare Pharmaceuticals INC. | $16.35 | 2023 | |
| Celgene Corporation | $15.99 | 2023 | Pomalyst |
| Cti Biopharma Corp. | $15.74 | 2022 | |
| Caris Mpi, INC. | $14.49 | 2025 | Mi Cancer Seek |
| Incyte Corporation | $13.82 | 2025 | Monjuvi |
| Spectrum Pharmaceuticals INC. | $13.64 | 2023 | Rolvedon |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Bock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.